Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astrazeneca Plc stock logo
AZN
Astrazeneca
$162.62
-1.3%
$169.73
$145.79
$212.71
$252.21B0.252.78 million shs3.07 million shs
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
$21.59
-1.8%
$22.13
$20.43
$34.84
$71.06B0.59236,615 shs70,223 shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$46.59
-1.9%
$47.96
$35.12
$64.16
$208.02B0.7417.36 million shs6.21 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$28.42
-1.4%
$25.90
$23.58
$29.21
$161.98B0.3441.59 million shs23.78 million shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astrazeneca Plc stock logo
AZN
Astrazeneca
+1.79%+0.10%+5.68%-11.51%+0.26%
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
+1.95%+1.52%+3.73%-4.64%+1.10%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
+1.38%+2.56%+7.45%+10.54%-16.39%
Pfizer Inc. stock logo
PFE
Pfizer
-0.70%+2.91%+13.67%+10.66%+16.42%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astrazeneca Plc stock logo
AZN
Astrazeneca
$162.62
-1.3%
$169.73
$145.79
$212.71
$252.21B0.252.78 million shs3.07 million shs
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
$21.59
-1.8%
$22.13
$20.43
$34.84
$71.06B0.59236,615 shs70,223 shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$46.59
-1.9%
$47.96
$35.12
$64.16
$208.02B0.7417.36 million shs6.21 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$28.42
-1.4%
$25.90
$23.58
$29.21
$161.98B0.3441.59 million shs23.78 million shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astrazeneca Plc stock logo
AZN
Astrazeneca
+1.79%+0.10%+5.68%-11.51%+0.26%
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
+1.95%+1.52%+3.73%-4.64%+1.10%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
+1.38%+2.56%+7.45%+10.54%-16.39%
Pfizer Inc. stock logo
PFE
Pfizer
-0.70%+2.91%+13.67%+10.66%+16.42%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Astrazeneca Plc stock logo
AZN
Astrazeneca
2.75
Moderate Buy$206.6727.02% Upside
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
2.60
Moderate BuyN/AN/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.16
Hold$64.9439.39% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.19
Hold$28.28-0.52% Downside

Current Analyst Ratings Breakdown

Latest CHGCY, AZN, NVO, and PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/1/2026
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
UpgradeHold
8/31/2026
Pfizer Inc. stock logo
PFE
Pfizer
UpgradeHold (C-)Hold (C)
8/27/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
DowngradeHoldSell
8/23/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
Initiated CoverageOutperform$198.00
8/17/2026
Pfizer Inc. stock logo
PFE
Pfizer
DowngradeHold (C)Hold (C-)
8/12/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Set Price Target$47.00
8/12/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
DowngradeBuyHold
8/11/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
UpgradeStrong SellHold
8/7/2026
Pfizer Inc. stock logo
PFE
Pfizer
Lower Price TargetBuy$35.00 ➝ $31.00
8/6/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
Reiterated RatingMarket Perform$47.00
8/6/2026
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
DowngradeStrong-BuyHold
(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Astrazeneca Plc stock logo
AZN
Astrazeneca
$58.74B4.30$13.02 per share12.50$32.48 per share5.01
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
$8.41B8.45$0.95 per share22.75$3.88 per share5.57
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$46.80B4.44$4.67 per share9.98$6.58 per share7.08
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.59$4.31 per share6.60$15.00 per share1.90
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Astrazeneca Plc stock logo
AZN
Astrazeneca
$10.23B$6.6924.3314.351.2617.02%31.45%13.20%10/30/2026 (Estimated)
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
$2.91B$0.9223.4917.57N/A35.09%23.76%19.92%10/23/2026 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$15.51B$4.0911.3913.621.5735.36%61.20%21.49%11/4/2026 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$0.7637.419.671.956.80%19.63%8.46%11/3/2026 (Estimated)

Latest CHGCY, AZN, NVO, and PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.77$0.96+$0.19$0.72$10.89 billion$11.98 billion
8/4/2026Q2 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.6820$0.77+$0.0880-$0.04$14.40 billion$15.03 billion
7/27/2026Q2 2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
$2.50$2.63+$0.13$0.8050$15.44 billion$15.38 billion
7/24/2026Q2 2026
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
N/A$0.22N/A$0.22$2.38 billion$2.14 billion
6/30/2026Q2 2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
N/A$0.9440N/A$0.72N/A$11.98 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Astrazeneca Plc stock logo
AZN
Astrazeneca
$4.342.67%+2.30%64.87%N/A
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
$0.311.43%N/A33.70%N/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.821.76%+21.74%20.05%N/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.05%-13.20%226.32%16 Years

Latest CHGCY, AZN, NVO, and PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/24/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.01%7/24/20267/24/20269/1/2026
8/5/2026
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.57862.58%8/17/20268/17/20268/25/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Astrazeneca Plc stock logo
AZN
Astrazeneca
0.47
0.89
0.67
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
N/A
4.35
3.54
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.59
0.79
0.56
Pfizer Inc. stock logo
PFE
Pfizer
0.71
1.27
0.96

Institutional Ownership

CompanyInstitutional Ownership
Astrazeneca Plc stock logo
AZN
Astrazeneca
20.35%
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
0.01%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Astrazeneca Plc stock logo
AZN
Astrazeneca
N/A
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
N/A
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
CompanyEmployeesShares OutstandingFree FloatOptionable
Astrazeneca Plc stock logo
AZN
Astrazeneca
96,1001.55 billionN/AN/A
Chugai Pharmaceutical Co., Ltd. Unsponsored ADR stock logo
CHGCY
Chugai Pharmaceutical
7,7783.29 billionN/ANot Optionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
69,5054.47 billion4.46 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable

Recent News About These Companies

Pfizer (PFE) Stock Looks Fully Valued As Earnings Run Ahead Of Value
3 Things You Need to Know If You Buy Pfizer Stock Today
3 Things You Need to Know If You Buy Pfizer Stock Today
Medicus Pharma inks deal with Pfizer to advance clinical-stage ADC
Pfizer's Pipeline Strategy Centers on Obesity and Oncology
Pfizer (PFE) Up 12.4% Since Last Earnings Report: Can It Continue?
Pfizer's Pipeline Strategy Centers on Obesity and Oncology

New MarketBeat Followers Over Time

Media Sentiment Over Time

Astrazeneca stock logo

Astrazeneca NYSE:AZN

$162.62 -2.15 (-1.30%)
As of 03:58 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Chugai Pharmaceutical stock logo

Chugai Pharmaceutical OTCMKTS:CHGCY

$21.59 -0.40 (-1.82%)
As of 03:59 PM Eastern

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$46.59 -0.92 (-1.94%)
As of 03:58 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Pfizer stock logo

Pfizer NYSE:PFE

$28.42 -0.39 (-1.35%)
As of 03:58 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.